Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial

Name: Verified Rigor Record — Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial
Item: Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial
Rating: 96
Author: Αlpha¹

Attard G, Agarwal N, Graff JN, Sandhu S, Efstathiou E, Özgüroğlu M, Pereira de Santana Gomes AJ, Vianna K, Luo H, Gotto GT, Cheng HH, Kim W, Varela CR, Schaeffer D, Kramer K, Li S, Baron B, Shen F, Mundle SD, McCarthy SA, Olmos D, Chi KN, Rathkopf DE.

Paper source

Open DOI

Αlpha¹ Rigor Review

Rigor Review Verified

Critical

High-priority

Action items to resolve · Critical / High

Confidence: highEngine: 7.6.0Source: full text

This Alpha1 Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The manuscript reports a well-designed phase 3 trial with rigorous methodology and transparent reporting. The main weakness is the absence of code sharing and minor imprecision in statistical reporting (p-value thresholds, missing data handling).

Three independent rigor evaluations were synthesized; the reviewers largely agreed, with minor divergence on statistical analysis and data code availability (resolved by weighing evidence). Study type is interventional (human RCT). Many checklist items (e.g., antibodies, cell lines) are not applicable.

12 major claims checked against the paper's own evidence: all adequately supported.

supportedAbstractReviewer 1
Combining niraparib with AAP significantly improved radiographic progression-free survival in patients with mCSPC harboring BRCA1/BRCA2 or other HRR gene alterations.
The claim is supported by the primary endpoint results showing a statistically significant improvement in radiographic progression-free survival in the BRCA subgroup (HR=0.52, p<0.0001), HRR effector subgroup (HR=0.57, p=0.0003), and ITT population (HR=0.63, p=0.0001).
Evidence: Results, Efficacy: primary endpoint, Figures 2a-c
“Combining niraparib with AAP significantly improved radiographic progression-free survival in patients with mCSPC harboring BRCA1/BRCA2 or other HRR gene alterations, suggesting clinical benefit with this combination for these patients.”
supportedDiscussion, final paragraphReviewer 1
The combination of niraparib and abiraterone plus prednisone was associated with significantly longer radiographic progression-free survival in patients with mCSPC with HRR gene alterations.
This claim is directly supported by the primary analysis results in the ITT population.
Evidence: Results, Efficacy: primary endpoint, Figure 2c
“The combination of niraparib and abiraterone plus prednisone was associated with significantly longer radiographic progression-free survival in patients with mCSPC with HRR gene alterations.”
supportedDiscussion, final paragraphReviewer 1
The reduction in radiographic progression is clinically significant, most notably in cancers with a BRCA1/2 mutation.
The claim is supported by the larger effect size in the BRCA subgroup (HR=0.52) compared to the ITT population (HR=0.63), and the statistically significant results.
Evidence: Results, Efficacy: primary endpoint, Figures 2a and 2c
“The reduction in radiographic progression is clinically significant, most notably in cancers with a BRCA1/2 mutation, and this combination could represent a new treatment option for such patients.”
supportedDiscussion, final paragraphReviewers 1, 2
This is, to our knowledge, the first demonstration of efficacy of a PARP inhibitor in mCSPC.
The paper presents the first phase 3 trial of a PARP inhibitor in mCSPC, and the results are positive. This claim is supported by the study design and results, and the authors acknowledge the novelty.
Evidence: Entire study results
“In conclusion, this is, to our knowledge, the first demonstration of efficacy of a PARP inhibitor in mCSPC.”
supportedDiscussion, final paragraphReviewer 1
The potential benefits of the prolonged radiographic progression-free survival with this treatment regimen should be considered in the context of the potential risks of adverse events in this population of patients with mCSPC.
The paper provides comprehensive safety data, including higher rates of grade 3/4 adverse events (75% vs 59%), more treatment-emergent deaths (14 vs 7), and a case of MDS. The claim is a balanced interpretation of the risk-benefit profile.
Evidence: Results, Safety, Table 2, Extended Data Tables 5-7
“The potential benefits of the prolonged radiographic progression-free survival with this treatment regimen should be considered in the context of the potential risks of adverse events in this population of patients with mCSPC.”
supportedAbstract, ResultsReviewer 2
The addition of niraparib to abiraterone plus prednisone results in longer radiographic progression-free survival in mCSPC with HRR gene alterations.
The primary endpoint result supports this claim with a statistically significant hazard ratio.
Evidence: Radiographic progression-free survival analysis: HR=0.63 (95% CI 0.49-0.80), P=0.0001 in the ITT population.
“The primary endpoint was met, with a significant improvement in radiographic progression-free survival ... in the intention-to-treat population (hazard ratio = 0.63; 95% confidence interval: 0.49–0.80; P = 0.0001)”
supportedAbstract, DiscussionReviewer 2
Combining niraparib with AAP significantly improved radiographic progression-free survival in patients with mCSPC harboring BRCA1/BRCA2 or other HRR gene alterations, suggesting clinical benefit with this combination for these patients.
The primary endpoint was met, and the benefit is clearest in the BRCA subgroup.
Evidence: Statistically significant improvement in rPFS in the ITT population and the BRCA subgroup.
“Combining niraparib with AAP significantly improved radiographic progression-free survival in patients with mCSPC harboring BRCA1/BRCA2 or other HRR gene alterations, suggesting clinical benefit with this combination for these patients.”
supportedAbstract, ResultsReviewer 2
The data for overall survival ... favor niraparib.
The hazard ratio point estimates favor niraparib, but the data are immature and not statistically significant, so the claim is appropriately cautious as the paper labels it as a secondary endpoint.
Evidence: Overall survival HR = 0.79 (95% CI 0.59-1.04), P=0.10, which is not significant.
“The data for overall survival, a key secondary endpoint, are immature (193/389 events) but favor niraparib (hazard ratio = 0.79 (95% confidence interval: 0.59–1.04); BRCA subgroup: hazard ratio = 0.75 (95% confidence interval: 0.51–1.11)).”
supportedAbstract; Results, Efficacy: primary endpointReviewer 3
Niraparib plus AAP significantly improves radiographic progression-free survival in patients with HRR-deficient mCSPC.
The paper presents the primary endpoint analysis with HR=0.63 (95% CI 0.49–0.80; P=0.0001) in the ITT population and consistent results in pre-specified subgroups.
Evidence: Figure 2, Results section, primary endpoint analysis.
“Combining niraparib with AAP significantly improved radiographic progression-free survival in patients with mCSPC harboring BRCA1/BRCA2 or other HRR gene alterations, suggesting clinical benefit with this combination for these patients.”
supportedResults, Efficacy: primary endpoint; Discussion, paragraph 2Reviewer 3
The benefit is greatest in patients with BRCA1/2 alterations.
The HR for rPFS in the BRCA subgroup is 0.52 (0.37–0.72) compared to 0.63 (0.49–0.80) in ITT; the paper numerically shows greater benefit.
Evidence: Figure 2a-c; Discussion states 'the magnitude of benefit ... was numerically greater in the BRCA subgroup than in the intention-to-treat population'.
“The magnitude of benefit for both radiographic progression-free survival and overall survival was numerically greater in the BRCA subgroup than in the intention-to-treat population.”
supportedResults, Secondary endpoints; AbstractReviewer 3
Overall survival data are immature but favor niraparib.
The paper clearly states that OS data are immature (193/389 events), and reports HR=0.79 (0.59–1.04) with P=0.10, calling it 'not sufficiently mature to detect a significant improvement'.
Evidence: Results, Secondary endpoints; Discussion.
“The data for overall survival, a key secondary endpoint, are immature (193/389 events) but favor niraparib (hazard ratio = 0.79 (95% confidence interval: 0.59–1.04); BRCA subgroup: hazard ratio = 0.75 (95% confidence interval: 0.51–1.11)).”
supportedResults, Safety; Discussion, paragraph 4Reviewer 3
The safety profile is consistent with prior observations, with medically manageable toxicities.
The paper reports grade 3/4 adverse events, dose modifications, and discontinuations. It notes that anemia and hypertension were common but manageable. It states 'Adverse events were medically manageable with dose modifications and supportive care'.
Evidence: Results, Safety; Discussion.
“Adverse events were medically manageable with dose modifications and supportive care; there were few treatment discontinuations; and associated serious sequalae were rare.”

Recomputed 10 tests: 7 consistent, 3 inconsistent, 10 via agent-written checks.

Rigor

Eight Dimensions7 pass · 1 warn

12 major claims12 supported

5 copyedit issues flagged: mostly consistency, clarity, other.

Checked 45 references: 43 verified — 2 not checked.

Reproducibility

2 data/code links checked; 2 live.

datahttp://yoda.yale.eduLIVEHTTP 200
Resolves, but the content could not be matched to the paper.
datahttps://www.janssen.com/clinical-trials/transparencyLIVEHTTP 200
Resolves, but the content could not be matched to the paper.

Registered (5 IDs: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Alpha¹ Rigor Action ItemsFinal pass before journal submission

Ready after minor edits: the manuscript is methodologically sound, but adding a code sharing statement, clarifying missing data handling, and fixing a few copyedit errors will strengthen the submission and address potential reviewer concerns.

1.
HIGHdata code
Add a code sharing statement to the Data availability section: provide a link to a public repository (e.g., GitHub, Zenodo) with the custom SAS analysis code, or state that code is available upon request from the corresponding author.
No analysis code is currently reported; sharing code enhances reproducibility and is expected by many journals.
2.
HIGHreporting
In the Methods, Statistical analysis section, clarify the handling of missing data beyond the 'data-as-observed' approach; specify whether a complete-case or available-case analysis was used and describe any sensitivity analyses.
The current description is vague and was flagged by both a reviewer and the copyedit pass; clearer reporting strengthens the analysis credibility.
3.
HIGHcopyedit
In Methods, Trial design and participants, correct 'International Counsel for Harmonisation' to 'International Council for Harmonisation' (ICH).
The current phrasing is a misspelling of the standard organization name.
4.
MEDIUMstatistics
In Results, provide exact p-values (e.g., P=0.00012) instead of inequality values like P < 0.0001 where possible, or report them in the supplementary materials.
Exact p-values allow readers to assess the strength of evidence more precisely, though thresholds are standard for very small values.
5.
MEDIUMstatistics
In Methods, Statistical analysis, add a brief verification of the proportional hazards assumption for the Cox models (e.g., a test or scaled Schoenfeld residuals plot in the supplementary materials).
While not always required, verifying this assumption would address a reviewer concern and improve analytic rigor.
6.
MEDIUMreporting
In Methods, Trial design and participants, provide more detailed description of blinding procedures: specify who was blinded (patients, investigators, outcomes assessors) and how blinding was maintained (e.g., matching placebos).
The current description is brief; fuller details help confirm internal validity.
7.
MEDIUMstatistics
In Results, report effect sizes for secondary endpoints (e.g., time to PSA progression, overall survival at interim) with confidence intervals consistently in the main text, not only p-values.
Ensures uniform reporting of effect precision across all outcomes.
8.
MEDIUMdata code
Consider depositing de-identified genomic sequencing data from the central assays (FoundationOne CDx, etc.) in a public repository such as dbGaP or EGA, and cite the accession number in the Data availability section.
Enables data reuse for validation and secondary research, aligning with genomic data sharing best practices.
9.
MEDIUMreporting
In Results, Secondary endpoints, rephrase the long sentence about subsequent treatments in the abiraterone group for clarity (see copyedit suggestion).
Improves readability and avoids potential misinterpretation.
10.
LOWreporting
In Results, add a CONSORT flow diagram with detailed reasons for screen failures and exclusions (Figure 1 may already be present but ensure it is fully detailed).
Provides complete transparency about patient flow, a standard for RCTs.
11.
LOWreporting
In Methods, Participants, consider specifying 'deleterious or suspected deleterious' instead of just 'deleterious' for HRR gene alterations, if applicable.
Aligns with common trial terminology and avoids ambiguity about pathogenicity classification.
12.
LOWcopyedit
In Results, Table 1, ensure the note about percentages not summing to 100 due to rounding is clear; add a statement if multi-answer options apply.
Standard practice for categorical data presentation.
13.
LOWreporting
In Results, for patient-reported outcomes (FACT-P), consider reporting the minimal clinically important difference (MCID) to help interpret clinical significance.
Helps readers assess whether changes are clinically meaningful, not just statistically significant.

Full text (59,121 chars)Analyzed: Jul 6, 2026

Αlpha¹ assesses methodological rigor, not the importance of the findings. See how we calibrate →